Anaheim, Calif. & Charleston, S.C. & Oakdale, Minn., July 18, 2019 – Veravas, Inc., is showcasing for the first time, a newly launched portfolio of laboratory products to detect and manage biotin interference at the American Association for Clinical Chemistry (AACC) annual meeting on August 4-8, 2019 in Anaheim, California.
Joshua Soldo, Chief Scientific Officer, will be presenting on their patent pending technology and sample preparation products at the AACC Innovation Zone on Tuesday, August 6, from 12:00-12:10pm PT. The Innovation Zone is located in the exhibit hall. The company’s technology helps laboratory professionals detect, remove, and manage interferences that impact laboratory results while IVD manufacturers reformulate their immunoassays to address biotin interference, ultimately helping make diagnostic tests more accurate and reliable.
Veravas will also be hosting a workshop, “Immunoassay Interferences and Their Impact on Patient Care,” on Wednesday, August 7, from 7:00-8:30am PT at the Hilton Anaheim in room California B. In this free workshop, lab medicine experts from Mayo Clinic in Rochester, Minnesota, and Biochimie Médicale in Brussels, Belgium, will discuss how common immunoassay formats cause falsely elevated or suppressed test results, the impact this has on patient care and outcomes, and currently available strategies to troubleshoot for biotin interference.
The initial set of Veravas products focuses on addressing the issue of biotin interference specifically, which can cause false or misleading results with tests that use biotin/avidin technology common in many immunoassay diagnostic tests.
Veravas will be showcasing these products at booth #1469.
These products are for Research Use Only (RUO).
Veravas is transforming laboratory medicine with technology that delivers superior test results, providing confidence to clinicians and patients that diagnoses are accurate. The company is rapidly driving the commercialization of proprietary sample preparation products and new diagnostic tests. Veravas’ nano magnetic particles can identify, remove, and measure select substances from patient samples to reduce the effects of complex interferences and detect low-abundance biomarkers. Led by a passionate and dedicated team, Veravas is devoted to improving patient lives by minimizing the harmful effects of unnecessary treatments and deaths associated with poor quality diagnostic results. Because every patient deserves the correct result, every time. To learn more about our technologies and clinical applications, visit veravas.com.